A partnership involving Parkinson's UK has been recognised at the Made with Patients awards, organised by Patient Focused Medicines Development.
Campaigners are calling for the prescription charge exemption list in England to be reviewed following the price rise.
We're providing £2.1million through our Virtual Biotech programme to develop a potential new drug which holds promise for protecting brain cells in Parkinson's.
The TOP HAT trial is closing early and we have an important update on next steps.
Parkinson's UK has funded two future leaders in Parkinson's research who are pushing forward our understanding of the early stages and causes of Parkinson's.
Early research shows transplanting gut bacteria from healthy individuals to people with Parkinson's, called a faecal microbiota transplant, is safe and may ease motor symptoms.
Lixisenatide, a diabetes drug being investigated for Parkinson's, shows potential to slow the progression of movement symptoms.
New research study shows impact of delirium for people with Parkinson's in hospital
The simple skin test was able to detect a troublesome protein associated with Parkinson's and other similar conditions.
Our latest round of grants fund projects which aim to improve everyday life for people living with Parkinson's, without the need for extra medications.
Patient groups, healthcare professionals and NHS England came together to take action to ensure people in hospital get their medication on time, every time.
We're teaming up with Walking Football Scotland to give people with Parkinson's more opportunities to play the game.
Foslevodopa-foscarbidopa (also called Produodopa) has been approved by NICE in England, Northern Ireland and Wales and the Scottish Medicines Consortium for people with Parkinson's who experience movement related symptoms.
Foslevodopa-foscarbidopa (also called Produodopa) can be offered in England from 27 February for people with Parkinson's who experience movement related symptoms.
Produodopa, a groundbreaking new treatment for advanced Parkinson's, can now be prescribed in Scotland.
A further trial of a device-delivered GDNF is not going ahead, but other approaches are showing promise.
At the end of March, the government's cost of living support will come to an end. Yet our new research has found that for many people with Parkinson's, the cost of living crisis is far from over.
Predict-PD is a study that aims to understand the risk factors of Parkinson's. More than 10,000 people are now taking part and are representative of the ethnic diversity within the UK population.